Work

MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma

Year: 2023

Type: editorial

Abstract: SUMMARY: In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint. See related article by Paiva et al., p. 365 (1).

Source: Blood Cancer Discovery

DOI: 10.1158/2643-3230.bcd-23-0134

Authors: Ola Landgren, Dickran Kazandjian

Institutions: University of Miami, Sylvester Comprehensive Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Sylvester Comprehensive Cancer Center, University of Miami Health Systems, National Cancer Institute